Interim Data Suggest Clinical Improvement Occurring With Nanocrystalline Gold Treatment of Multiple Sclerosis

Updated interim data from 2 Phase 2 clinical trials support CNM-Au8, a catalytically active gold nanocrystal suspension, as a potential disease-modifying therapy for multiple sclerosis (MS).  

Data from the Phase 2 VISIONARY-MS study (NCT03536559) suggest treatment with nanocrystalline gold (CNM-Au8; (Clene Nanomedicine, Salt Lake City, UT) is leading to clinical improvement for multiple sclerosis. Clinically relevant improvement in the study is measured as change from baseline in the modified MS Functional Composite (MSFC). MSFC scores were significantly improved across the entire, as yet unblinded, study population compared with baseline after 48 weeks of treatment (P<.0001). Improvements across the entire study population in the specific MSFC domains of the symbol digit modalities test (SDMT) and the 9-hole peg test, suggesting that limb function and cognition were improving. 

These data were included in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022 on February  24-26.